Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
FDA might mandate drug training
Perhaps triplicate prescriptions are not enough of a safety measure when it comes to powerful narcotics. At least, that's what the FDA might be thinking. The agency is considering mandatory training for clinicians who prescribe certain narcotic medications, including methadone, fentanyl and some versions of oxycodone.
It's a move that would be controversial and one that the FDA cannot make in a vacuum, according to Bob Rappaport, the agency's director for the division of Anesthesia, Analgesia and Rheumatology Products, as states usually have jurisdiction over regulatory and education issues when it comes to physicians.
As it stands, a state medical license and a simple registration with the Drug Enforcement Administration are all that are necessary for a physician to prescribe narcotics. At present, states like California that require additional training are the exception rather than the norm.
- read the full story in the New York Times
Related Articles:
FDA finally gets long-awaited funds
FDA recruits a new generation of drug regulators
Grassley, Dingell plan FDA renovation
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


